Actively Recruiting
Enavogliflozin vs. Pioglitazone on Glucose and Atherosclerosis
Led by Seoul National University Bundang Hospital · Updated on 2026-05-05
120
Participants Needed
1
Research Sites
204 weeks
Total Duration
On this page
Sponsors
S
Seoul National University Bundang Hospital
Lead Sponsor
D
Daewoong Pharmaceutical Co. LTD.
Collaborating Sponsor
AI-Summary
What this Trial Is About
The current study aimed to thoroughly compare a thiazolidinedione and an sodium-glucose cotransporter-2 (SGLT2) inhibitor regarding various clinical issues including atherosclerosis. Enavogliflozin is compared to Pioglitazone in the glucose-lowering effects of adding to the treatment of patients with type 2 diabetes whose HbA1c levels are not controlled by Metformin with or without DPP-4 inhibitors. Additionally, the study will compare changes in other metabolic or cardiovascular risk factors, such as triglycerides, high density lipoprotein cholesterol (HDLc), uric acid, blood pressure, and inflammatory markers, between the two drugs.
CONDITIONS
Official Title
Enavogliflozin vs. Pioglitazone on Glucose and Atherosclerosis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Type 2 diabetes patients with a glycated hemoglobin (HbA1c) level of 7.0 - 10.5% at screening
- Males or females aged 20-80 years
- Individuals who have been taking Metformin (≥ 500mg) with or without a DPP-4 inhibitor for at least the past 3 months
- Body mass index ≥ 23 kg/m²
- Estimated glomerular filtration ratio (eGFR) ≥ 60 ml/min/1.73m²
You will not qualify if you...
- Patients with Type 1 Diabetes, Gestational Diabetes, or secondary diabetes due to other causes
- Patients with a history of acute cardiovascular disease within the last 3 months prior to the screening visit
- Pregnant or breastfeeding patients, or patients not using contraception
- Patients with chronic Hepatitis B or C (excluding healthy carriers of Hepatitis B), or liver disease with AST and/or ALT > 3 times the upper limit of normal
- Patients with heart failure or a history of heart failure
- Individuals with a history of cancer within the past 5 years (excluding those adequately treated for squamous cell carcinoma or thyroid cancer)
- Patients who have participated in another clinical study within the last 30 days
- Alcohol addiction
- Patients for whom the use of Enavogliflozin or Pioglitazone is contraindicated
- Patients taking other oral hypoglycemic agents or insulin or other investigational drugs
- Patients deemed unsuitable for the study based on the investigator's judgment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, South Korea, 13620
Actively Recruiting
Research Team
S
Soo Lim, M.D. Ph.D.
CONTACT
M
Minji Sohn, Ph.D.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here